trending Market Intelligence /marketintelligence/en/news-insights/trending/YOMoZHw5BvP2hdvAsW16yQ2 content esgSubNav
In This List

Flexion's osteoarthritis drug Zilretta wins US FDA approval

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Flexion's osteoarthritis drug Zilretta wins US FDA approval

The U.S. Food and Drug Administration approved Flexion Therapeutics Inc.'s non-opioid drug Zilretta, an intra-articular injection for osteoarthritis knee pain.

The FDA approval is based upon data from Flexion's pivotal phase 3 clinical trial.

Zilretta's label also includes the results from a trial that examined blood glucose concentrations in patients with type 2 diabetes. The trial found that Zilretta may avoid the spikes in blood sugar associated with the use of corticosteroid treatment in patients with both knee pain and diabetes.

Flexion expects Zilretta will be available in the U.S. by the end of October.